These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24929963)

  • 21. [Use of 11F-fluorothymidine positron emission tomography in brain tumor].
    Kawai N; Kagawa M; Miyake K; Nishiyama Y; Yamamoto Y; Shiraishi H; Ichikawa T; Tamiya T
    No Shinkei Geka; 2009 Jul; 37(7):657-64. PubMed ID: 19621774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas.
    Gempt J; Bette S; Ryang YM; Buchmann N; Peschke P; Pyka T; Wester HJ; Förster S; Meyer B; Ringel F
    Eur J Radiol; 2015 May; 84(5):955-62. PubMed ID: 25748815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
    Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
    J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival.
    Belohlavek O; Fencl P; Majovsky M; Jaruskova M; Benes V
    Nucl Med Rev Cent East Eur; 2014; 17(1):7-12. PubMed ID: 24610646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
    Wardak M; Schiepers C; Dahlbom M; Cloughesy T; Chen W; Satyamurthy N; Czernin J; Phelps ME; Huang SC
    Clin Cancer Res; 2011 Oct; 17(20):6553-62. PubMed ID: 21868765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas.
    Collet S; Valable S; Constans JM; Lechapt-Zalcman E; Roussel S; Delcroix N; Abbas A; Ibazizene M; Bernaudin M; Barré L; Derlon JM; Guillamo JS
    Neuroimage Clin; 2015; 8():448-54. PubMed ID: 26106569
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas.
    Yamamoto Y; Ono Y; Aga F; Kawai N; Kudomi N; Nishiyama Y
    J Nucl Med; 2012 Dec; 53(12):1911-5. PubMed ID: 23081994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study for texture analysis of
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI.
    Khangembam BC; Sharma P; Karunanithi S; Singhal A; Das CJ; Kumar P; Julka PK; Bandopadhyaya GP; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2013 Nov; 34(11):1046-54. PubMed ID: 24025920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI.
    Singhal T; Narayanan TK; Jacobs MP; Bal C; Mantil JC
    J Nucl Med; 2012 Nov; 53(11):1709-15. PubMed ID: 23055534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
    Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
    Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.